Mario Mandalà on Muck Rack

Mario Mandalà

Perugia
As seen in: Nature, Wiley Online Library, American Journal of Clinical Dermatology, The BMJ, The New England Journal of Medicine, The Lancet, Future Medicine, EMJ- European Medical Journal, European Journal of Cancer, Cancer Treatment Reviews and
Associate professor of Medical Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mario

Contact Mario, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases

|
By Mario Mandalà, Monica Chen Verified, Ryan Sullivan
| The BMJ Verified
The optimal duration of immune checkpoint inhibitor therapy in melanoma brain metastases remains unclear. Discontinuation of nivolumab plus ipilimumab within 24 months after response is associated with survival outcomes comparable to continued treatment, and discontinuation after complete response—including due to toxicity—can result in durable disease control. Immune-related adverse events are associated with improved overall survival, independent of anti-tumor necrosis factor-alpha use.
Open in Who Shared Issue with article?

Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial | Nature Medicine

|
By Georgina V. Long, Daniel Marbach, Richard A. Scolyer, Nicolas Staedler, Rodabe N. Amaria, Paolo Antonio Ascierto, Ahmad A Tarhini, Caroline Robert, Eva Muñoz-Couselo, Giuseppe Curigliano, Mario Mandalà, Uwe Bader
| Nature Verified
Abstract Patients with stage III melanoma are at high risk of relapse. The NADINA trial evaluating neoadjuvant nivolumab plus ipilimumab and the SWOG-1801 trial evaluating neoadjuvant pembrolizumab have demonstrated superior clinical outcomes with neoadjuvant versus adjuvant checkpoint inhibition.
Open in Who Shared Issue with article?

Tumour microenvironment heterogeneity in primary and metastatic paired melanoma samples and its correlation with genetic features and prognosis

|
By Mario Mandalà, Maria Sini, Lorenzo Caldirola, Sara Simi
| European Journal of Cancer Verified
aUnit of Medical Oncology, Department of Medicine and Surgery, University of Perugia, 06156 Perugia, Italy bHistopathology and Molecular Diagnostics, Careggi University Hospital, 50139 Florence, Italy cMethodology for Clinical Research Laboratory, Clinical Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy dUnit of Cancer Genetics, Institute of Genetic Biomedical Research (IRGB), National Research Council (CNR), 07100 Sassari, Italy; Immuno-Oncology...
Open in Who Shared Issue with article?
See all 32 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified